Related Experiment Videos
A comparative study on glucagon effect between McArdle disease and Tarui disease
Muscle & Nerve
|September 1, 1984
Summary
Glucagon benefits McArdle disease patients by improving exercise performance and relieving muscle symptoms. This effect, linked to enhanced glucose utilization, was not observed in Tarui disease patients.
Area of Science:
- Biochemistry
- Exercise Physiology
- Metabolic Myopathies
Background:
- McArdle disease and Tarui disease are inherited metabolic myopathies affecting muscle glycogen metabolism.
- Understanding differential responses to metabolic interventions can elucidate disease mechanisms.
Observation:
- Glucagon pretreatment improved exercise performance and reduced muscle symptoms in McArdle disease but not Tarui disease.
- Exercise-induced lactate production increased significantly post-glucagon in McArdle disease, unlike in Tarui disease.
- Glucose or glucose plus insulin administration augmented exercise-induced lactate in McArdle disease, but insulin alone, arginine, or epinephrine did not.
Findings:
- Glucagon's beneficial effect in McArdle disease is associated with enhanced muscle glucose utilization.
- This enhanced utilization appears dependent on the combined presence of hyperglycemia and hyperinsulinemia.
Implications:
- Glucagon may be a therapeutic option for managing exercise intolerance in McArdle disease.
- The distinct responses highlight key differences in glycolytic pathway regulation between McArdle and Tarui diseases.